Table 3. Clinicopathological characteristics of patients with EBVaGC based on LMP2A expression.
| LMP2A Positive N (%) | LMP2A Negative N (%) | †p | |
|---|---|---|---|
| Gender | 0.08 | ||
| Male | 26 (76.5) | 40 (90.9) | |
| Female | 8 (23.5) | 4 (9.1) | |
| Age (years) | 0.465 | ||
| ≤40 | 6 (17.5) | 11 (25.0) | |
| 40~60 | 21 (61.9) | 21 (47.7) | |
| >60 | 7 (20.6) | 12 (27.3) | |
| Lauren | 0.934 | ||
| Intestinal | 8 (23.5) | 10 (22.7) | |
| Diffuse | 26 (76.5) | 34 (77.3) | |
| Clinical Stage (pTNM)|| | 0.503 | ||
| I, II | 10 (29.4) | 10 (22.7) | |
| III, IV | 24 (70.6) | 34 (77.3) | |
| Invasion | 0.436 | ||
| T1,T2 | 6 (17.6) | 4 (9.1) | |
| T3,T4 | 28 (82.4) | 40 (90.9) | |
| Nodal status | 1.000 | ||
| N− | 7 (20.6) | 9 (20.5) | |
| N+ | 27 (79.4) | 35 (79.5) | |
| Distant metastasis | 1.000 | ||
| M0 | 34 (100) | 42 (95.5) | |
| M1 | 0 | 2 (4.5) | |
| HER2 | 0.073 | ||
| 0/1+ | 34 (100) | 40 (90.9) | |
| 2+ | 0 | 3 (6.8) | |
| 3+ | 0 | 1 (2.3) | |
†
p-values were obtained from Pearson Chi-Square tests, Continuity Correction or Kruskal Wallis Test.
||
AJCC TNM cancer staging system.